Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Erlotinib orally days 1-28 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Gemcitabine 1000 mg/m2 iv days 1, 8, 15 of a 28 day cycle | DRUG | - |
| Capecitabine orally days 1 -21 | DRUG | - |
| Erlotinib 100 mg orally days 1-28 | DRUG | - |
| Bevacizumab 5 mg/kg intravenously every 2 weeks | DRUG | - |
DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed adenocarcinoma of the pancreas * Locally advanced or metastatic disease * Not amenable to curative resection * No invasion of adjacent organs (e.g., duodenum or stomach) by CT scan * Unidimensionally measurable disease as assessed...
Top 20 of 69 competitors
Erlotinib orally days 1-28 is an oral dosing schedule of erlotinib, a small molecule EGFR inhibitor, given once daily on days 1 through 28 of a treatment cycle. It is being studied in pancreatic cancer. The regimen is also referred to as Erlotinib 100 mg orally days 1-28.
Erlotinib orally days 1-28 is used in pancreatic cancer as part of a combination regimen. In the Phase 1 trial NCT00260364, it was given with bevacizumab plus gemcitabine and capecitabine to treat advanced pancreatic cancer. The study enrolled 44 adults in the United Kingdom.
Erlotinib orally days 1-28 targets EGFR, the epidermal growth factor receptor. It is an EGFR inhibitor, a small molecule that blocks EGFR signaling. This mechanism underlies its investigation in pancreatic cancer, where EGFR pathway activity is relevant to tumor growth.
Erlotinib orally days 1-28 is developed by Roche Holding AG, which trades under the ticker RHHBY. Roche is the company associated with this oral erlotinib regimen and the Phase 1 pancreatic cancer study evaluating it.
Erlotinib orally days 1-28 is in Phase 1 development. It is investigational and has not been approved for pancreatic cancer. The single Phase 1 trial, NCT00260364, has been completed, and no active trials are ongoing for this regimen.
Erlotinib orally days 1-28 was evaluated in one completed Phase 1 trial, NCT00260364, titled Combining Erlotinib Plus Bevacizumab and Gemcitabine Plus Capecitabine to Treat Advanced Pancreatic Cancer. The trial enrolled 44 participants in the United Kingdom and was uncontrolled, non-randomized, and not double-blind.